Restarting Immunotherapy After Pneumonitis — Is It Ever Possible?

This page explains how the decision to restart immunotherapy after a resolved episode of pneumonitis is made. It is not for new or worsening breathlessness happening today — that is a separate emergency, whether or not you are also thinking about a future restart, and it should never be watched at home while waiting for a scheduled review.

Sometimes, but it is not the default outcome. Whether immunotherapy is restarted after pneumonitis depends on how severe the reaction was graded, how completely it resolved on steroids, and how much benefit immunotherapy was providing before the reaction happened. NCCN and ASCO guidance on immune-related adverse events frames this as an individual decision made by your tumour board, weighed case by case rather than applied the same way to every patient.

This decision also considers what our companion page on immune pneumonitis symptoms covers in more depth: how the initial reaction was recognised and graded shapes everything that follows, including whether a restart is even on the table.

Severity grade is the single biggest factor in whether a restart is even considered. It is graded the same way the original reaction was graded — by symptoms, imaging, and how much oxygen support was needed — and that grade largely sets the ceiling on what happens next.

These are typical positions from NCCN and ASCO irAE management guidance, not fixed rules — your tumour board can still decide differently based on your specific case, including how well the cancer was responding before the reaction.

Recurrence is a real and meaningful risk, not a rare exception. A meaningful proportion of patients who restart immunotherapy after pneumonitis develop the reaction again, sometimes at a similar grade and occasionally at a higher one. This is exactly why NCCN and ASCO guidance recommends restarting only in carefully selected patients, and only alongside closer monitoring than before — earlier follow-up scans, a lower threshold for reporting new symptoms, and a clear plan for stopping again quickly if pneumonitis returns.

Because this risk is real, "feeling fine" after a restart is not the same as being in the clear — see New or Worsening Cough on Immunotherapy: When to Worry for the specific signs that need same-day reporting during and after a restart.

The restart decision is not made quickly, and neither is a recurrence something that shows up on day one — both follow a fairly predictable timeline that your care team plans around.

There is no single test that answers this question. Your tumour board works through a structured set of considerations, and the same three questions from earlier — is rechallenge possible, what grade allows it, and what recurrence risk you'd be accepting — sit inside a wider framework that also looks at your cancer itself, not just the lung reaction.

1. 1

   Confirm complete resolution first

   Symptoms, oxygen levels, and follow-up CT imaging must show the pneumonitis has genuinely cleared — a restart is not considered while still tapering steroids or with any residual symptoms.

2. 2

   Weigh the original severity grade

   Grade 1 reactions carry the most flexibility; Grade 3-4 reactions are the strongest reason to look at alternatives instead, as covered in the grading table above.

3. 3

   Assess how much benefit immunotherapy was providing

   If your cancer was responding well before the reaction and other options are limited, that benefit is weighed against the recurrence risk of restarting.

4. 4

   Consider what else is available

   If a suitable alternative treatment exists with a lower lung risk, your team may recommend that path instead of accepting the recurrence risk of a restart — restarting is one option among several, not the only one.

5. 5

   Agree a monitoring plan before, not after, restarting

   If restart is agreed, the monitoring schedule — earlier scans, specific symptoms to report same-day — is set in advance, not improvised once treatment resumes.

A decision not to restart is not the same as a decision to stop all treatment. Depending on your cancer type and how you responded before the reaction, your oncologist may discuss switching to a different systemic treatment approach, continuing a treatment that does not carry the same lung risk, or, in specific situations, a period of closely monitored surveillance. Which of these applies is specific to your case and is explained by your own oncology team, not something this page can generalise.

For patients and families weighing this alongside disease progression concerns, our page on chest tightness and wheezing during treatment is a useful companion read — breathlessness after a pneumonitis episode is not automatically a sign the cancer is progressing, but it is also not something to assume is "just the lungs healing" without being checked.

These companion pages cover other parts of the same lung and breathing irAE pathway — worth reading alongside this one, whichever stage you're at.

• Chest Tightness and Wheezing During Treatment — how to tell a routine treatment-related sensation from one that needs same-day review.
• Immune Pneumonitis: Cough and Breathlessness on Immunotherapy — how the original reaction is recognised and graded.
• New or Worsening Cough on Immunotherapy: When to Worry — the specific signs worth reporting the same day, especially important during a restart.
• Immunotherapy at CION Cancer Clinics — how we monitor and support patients through immune-related side effects, from the first infusion onward.

Restart Decisions Are Made Together, Not Alone

Patients weighing a restart after a confirmed immune reaction are supported by the same multidisciplinary team throughout.